<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01018693</url>
  </required_header>
  <id_info>
    <org_study_id>CVAK694A2205</org_study_id>
    <nct_id>NCT01018693</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Capacity of VAK694 When Combined With Allergen Immunotherapy to Bring About Specific Immune Tolerance</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled Trial to Determine the Capacity of VAK694 to Elicit Long Term Immune Tolerance When Combined With Subcutaneous Allergen Immunotherapy for the Treatment of Seasonal Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether VAK694 when combined with subcutaneous&#xD;
      immunotherapy leads to long term immune tolerance to allergen in individuals with seasonal&#xD;
      allergic rhinitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intra-dermal late phase response to allergen Measure: Wheal diameter</measure>
    <time_frame>10-12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the immunomodulatory activity of VAK694 Measure: IgE/IgG, Th1/Th2 cytokine expression, Treg induction</measure>
    <time_frame>10-12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of VAK694 combined with SCIT on the symptoms of seasonal allergic rhinitis Measure: mini-Respiratory Quality of Life Questionnaire (RQLQm) and visual analogue scale (VAS)</measure>
    <time_frame>10-12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To preliminarily assess the ability of VAK694 to reduce the side-effects of subcutaneous immunotherapy Measure: Frequency and severity of local and systemic reactions to immunotherapy</measure>
    <time_frame>10-12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>VAK694 AND Immunotherapy (alutard)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>: VAK694 placebo AND Immunotherapy (alutard)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VAK694 placebo AND Immunotherapy (alutard) placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAK694; Alutard Avanz SQ</intervention_name>
    <arm_group_label>VAK694 AND Immunotherapy (alutard)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAK694 placebo infusion; Alutard Avanz SQ</intervention_name>
    <arm_group_label>: VAK694 placebo AND Immunotherapy (alutard)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAK694 placebo infusion; Saline</intervention_name>
    <arm_group_label>VAK694 placebo AND Immunotherapy (alutard) placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of atopy, defined as a history of seasonal allergic rhinitis for at least 2&#xD;
             years (in relation to the grass pollen allergy season), and evidence of atopy, defined&#xD;
             as a positive skin prick test (wheal difference allergen - negative control at least 3&#xD;
             mm) to grass pollen allergen at screening.&#xD;
&#xD;
          -  Male or female subjects aged between 18 and 60 years (inclusive)&#xD;
&#xD;
          -  Female subjects must be of non-childbearing potential&#xD;
&#xD;
          -  Subjects must weigh at least 50 kg with a body mass index (BMI) within the range of 18&#xD;
             to 32 kg/m2 (inclusive)&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with intranasal corticosteroids within 28 days prior to the first dose.&#xD;
&#xD;
          -  History of asthma with treatment with inhaled or systemic corticosteroids within 6&#xD;
             months of the first dose.&#xD;
&#xD;
          -  History of COPD.&#xD;
&#xD;
          -  Any exposure to human monoclonal or polyclonal antibodies.&#xD;
&#xD;
          -  Any allergy immunotherapy within 3 years prior to screening.&#xD;
&#xD;
          -  Any prior grass pollen allergy immunotherapy.&#xD;
&#xD;
          -  FEV1 &lt; 70% of predicted at screening or baseline.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.hayfeverlondon.net</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>November 24, 2009</study_first_submitted>
  <study_first_submitted_qc>November 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Seasonal allergic rhinitis,</keyword>
  <keyword>late phase response,</keyword>
  <keyword>alutard avanz,</keyword>
  <keyword>immunotherapy,</keyword>
  <keyword>visual analogue scale,</keyword>
  <keyword>mini rhinitis quality of life,</keyword>
  <keyword>immune modulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

